Summary

Europe Neuroblastoma Drugs Market is valued approximately USD 190 million in 2023 and is anticipated to grow with a healthy growth rate of more than 5.96% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurred in young children below five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. European nations are constantly developing collaborations among universities, pharmaceutical firms, and medical associations to expedite the creation of novel neuroblastoma medications. By working together, resources, knowledge, and patient data may be shared, which facilitates the efficiency of clinical trials and expedites the approval of innovative treatments. Accordingly, the increasing emphasis on collaborative research and clinical trials is a key trend for Europe Neuroblastoma Drugs Market.

The growing emphasis on pediatric oncology, bolstered by amplified funding and investments, consequently expediting neuroblastoma drug advancements and driving market expansion. Also, the rising advanced diagnostics and treatment options, increasing fundings from public and private sectors plays a pivotal role in supporting the research initiatives and clinical trials for emerging drug candidates. Additionally, the designation of orphan drug status and associated market exclusivity emerge as pivotal drivers for propelling the growth of the neuroblastoma drugs market. Neuroblastoma's classification as a rare disease, its eligibility for orphan drug designation offers pharmaceutical firms’ substantial incentives to channel resources into drug development initiatives. Europe has a strong foundation in medical research and development, leading to the continuous discovery of innovative drugs and treatment modalities for neuroblastoma. Furthermore, Europe's well-developed healthcare infrastructure, including specialized pediatric oncology centers and access to advanced medical technologies, contributes to the effective diagnosis and treatment of neuroblastoma, supporting market expansion. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Europe Neuroblastoma Drugs Market growth between 2022 and 2032.

The key countries considered for the Europe Neuroblastoma Drugs Market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany is recorded with the substantial share in the Neuroblastoma Drugs Market. Factors such as rising development of novel drug development, along with the supportive government policies, funding initiatives, and regulatory frameworks. The country's strong focus on medical research and development fuels innovations in neuroblastoma drugs and treatment modalities, leading to the introduction of novel and effective therapies. The market in France, on the other hand, is expected to develop at the fastest rate over the forecast period.

Major market player included in this report are:
Recordati Group
AstraZeneca plc
Novartis AG
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Type
Chemotherapy
Immunotherapy
Others

By Route of Administration
Oral
Injectable

By Distribution Channel
Online
Offline
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Europe Neuroblastoma Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Europe Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Type
2.3.2. By Route of Administration
2.3.3. By Distribution Channel
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe Neuroblastoma Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe Neuroblastoma Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe Neuroblastoma Drugs Market Size & Forecasts by Type 2022-2032
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Others
Chapter 6. Europe Neuroblastoma Drugs Market Size & Forecasts by Route of Administration 2022-2032
6.1. Oral
6.2. Injectable
Chapter 7. Europe Neuroblastoma Drugs Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Online
7.2. Offline
Chapter 8. Europe Neuroblastoma Drugs Market Size & Forecasts by Country 2022-2032
8.1. U.K. Neuroblastoma Drugs Market
8.1.1. Type breakdown size & forecasts, 2022-2032
8.1.2. Route of Administration breakdown size & forecasts, 2022-2032
8.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2. Germany Neuroblastoma Drugs Market
8.3. France Neuroblastoma Drugs Market
8.4. Spain Neuroblastoma Drugs Market
8.5. Italy Neuroblastoma Drugs Market
8.6. Rest of Europe Neuroblastoma Drugs Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Recordati Group
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. AstraZeneca plc
9.3.3. Novartis AG
9.3.4. Company 4
9.3.5. Company 5
9.3.6. Company 6
9.3.7. Company 7
9.3.8. Company 8
9.3.9. Company 9
9.3.10. Company 10
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes